Study:
Randomized Phase III Trial of Cisplatin (NSC-119875) and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide (NSC-141540) in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells. It is
not yet known whether cisplatin combined with irinotecan is more effective than cisplatin
combined with etoposide in treating extensive-stage small cell lung cancer.
Purpose:
Randomized phase III trial to compare the effectiveness of cisplatin combined with
either irinotecan or etoposide in treating patients who have extensive-stage small cell lung
cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lung Cancer |
Drug: cisplatin
Drug: etoposide
Drug: irinotecan hydrochloride |
Phase 3 |
Verified by
Southwest Oncology Group
November, 2012
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00045162
Study Type: Interventional
Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Ronald B. Natale, MD., Principal Investigator
David R. Gandara, MD., Principal Investigator
Primo N. Lara, MD., Principal Investigator
James R. Jett, MD., Principal Investigator
Jane Carleton, MD., Principal Investigator